Adalimumab May Lessen Joint Damage in Psoriatic Arthritis
The FDA has approved an expanded indication for the human monoclonal antibody adalimumab (Humira, Abbott) that includes inhibiting structural joint damage and improving physical function in patients with psoriatic arthritis (PsA). This indication is in addition to the approval for PsA that was granted in October 2005.
This product is also approved for moderate-to-severe rheumatoid arthritis and active ankylosing spondylitis.
order imitrex
PsA, an autoimmune disorder, combines symptoms of arthritis, including joint pain and inflammation, and those of psoriatic skin disease, such as painful, raised red lesions covered by silvery-white scales. The additional indication was based on results from an extension of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).
